Key result
Low-molecular-weight heparins provide effective thromboprophylaxis for medically ill patients, with dalteparin reducing VTE by 45% without increasing bleeding risk.
Why the study?
Do low-molecular-weight heparins reduce venous thromboembolism in acutely ill medical patients?
Population
Acutely ill medical patients with risk factors for VTE
Comparison
Low-molecular-weight heparins vs Placebo
Design
Review
Authors
Loading...
LMWH thromboprophylaxis merits consideration in at-risk medical patients; reinforces efficacy data from PREVENT and MEDENOX.
Do low-molecular-weight heparins reduce venous thromboembolism in acutely ill medical patients?
Effect estimate: 45% reduction
LMWHs are effective and safe for VTE prophylaxis in acutely ill medical patients, supporting widespread adoption as recommended by ACCP guidelines.
Bergmann et al. (2005) conducted a review in Venous thromboembolism. Low-molecular-weight heparins (LMWHs) vs. Placebo was evaluated on Venous thromboembolism (VTE) (45% reduction). Low-molecular-weight heparins provide effective thromboprophylaxis for medically ill patients, with dalteparin reducing VTE by 45% without increasing bleeding risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: